Medical treatment of alcohol dependence: A systematic review

International Journal of Psychiatry in Medicine

Volumn 42, Issue 3, 2011, Pages 227-266

  Miller, Peter M ^a   Book, Sarah W ^a   Stewart, Scott H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

acamprosate; alcoholism; disulfiram; naltrexone; topiramate

Indexed keywords

ACAMPROSATE; DEPADE; DISULFIRAM; NALTREXONE; PLACEBO; RIBOFLAVIN; SERTRALINE; TOPIRAMATE; UNCLASSIFIED DRUG;

ALCOHOLISM; CINAHL; DRINKING BEHAVIOR; DRUG EFFICACY; EMBASE; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNET; MEDICAL LITERATURE; MEDLINE; OFF LABEL DRUG USE; PATIENT COUNSELING; PSYCHOSOCIAL ADJUSTMENT TO ILLNESS SCALE; PSYCHOSOCIAL CARE; PSYCINFO; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOLISM; DISULFIRAM; FRUCTOSE; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OFF-LABEL USE; TAURINE; TREATMENT OUTCOME;

EID: 84856409713     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.42.3.b     Document Type: Review

References (103)

1. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry Jul 2007;64(7):830-842. (Pubitemid 47026379)
2. Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C, Chaikledkaew U. The economic impact of alcohol consumption: A systematic review. Substance Abuse Treatment Prevalence Policy 2009;4(1):20-31.
3. Consumption WECoPRtA. WHO Expert Committee on problems related to alcohol consumption: Second report. World Health Organization Technical Report Service 2007;944:1-57.
4. Smothers GA, Yahr HT, Sinclair MD. Prevalence of current DSM-IV alcohol use disorders in short-stay, general hospital admissions, United States, 1994. Archives of Internal Medicine 2003;163:713-719. (Pubitemid 36343365)
5. Manwell LB, Fleming MF, Johnson K, Barry KL. Tobacco, alcohol, and drug use in a primary care sample: 90-day prevalence and associated factors. Journal of Addictive Disorders 1998;17(1):67-81. (Pubitemid 28156159)
6. US PTF. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse. Annals of Internal Medicine 2004;140:555-557.
7. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association May 3 2006;295(17):2003-2017. (Pubitemid 44794003)
8. Fiellin DA, Reid MC, O'Connor PG. New therapies for alcohol problems: Application to primary care. American Journal of Medicine Feb 15 2000;108(3):227-237. (Pubitemid 30100615)
9. National, Alcoholism IoAAa. Helping patients who drink too much: A clinician's guide. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2007.
10. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction Mar 2005; 100(3):281-292. (Pubitemid 40363434)
11. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996;17:1-12. (Pubitemid 26120810)
12. Wilson A, Davidson WJ, Blanchard R. Disulfiram implantation: A trial using placebo implants and two types of controls. Journal of Studies on Alcohol 1980; 41(5):429-436. (Pubitemid 10015225)
13. Johnsen J, Morland J. Disulfiram implant: A double-blind placebo controlled follow-up on treatment outcome. Alcoholism: Clinical and Experimental Research Jun 1991;15(3):532-536.
14. Malcolm MT, Madden JS, Williams AE. Disulfiram implantation critically evaluated. British Journal of Psychiatry 1974;125:485-489.
15. Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Annals of Internal Medicine Jun 1979;90(6):901-904. (Pubitemid 9229637)
16. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. Journal of the American Medical Association Sep 19 1986;256(11):1449- 1455. (Pubitemid 16014332)
17. Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, et al. Disulfiram treatment of alcoholism. British Journal of Psychiatry Jul 1992;161:84-89.
18. De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol and Alcoholism Nov-Dec 2004;39(6):528-531. (Pubitemid 39534536)
19. Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism Jan-Feb 2008;43(1): 53-61.
20. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biology and Psychiatry May 15 2005;57(10):1128-1137. (Pubitemid 40615774)
21. De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism Nov-Dec 2005;40(6):545-548. (Pubitemid 41600008)
22. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. Journal of Substance Abuse Treatment Jun 2008;34(4):460-463. (Pubitemid 351609293)
23. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction Dec 2008;103(12): 2035-2044.
24. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet May 17 2003;361(9370):1677-1685. (Pubitemid 36577440)
25. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: A randomized controlled trial. Journal of the American Medical Association Oct 10 2007;298(14):1641-1651. (Pubitemid 47606653)
26. Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcoholism: Clinical and Experimental Research Jul 2008;32(7):1251-1259.
27. Moak D, Anton R, Latham PK, Voronin KE, Waid RL, Durazo-Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics: Results of a placebocontrolled trial. Journal of Clinical Psychopharmacology 2003;23(6):553-563.
28. Pettinati H, Volpicelli JR, Luck G, Kranzler H, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. Journal of Clinical Psychopharmacology 2001;21(2):143-153. (Pubitemid 32221051)
29. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcoholism: Clinical and Experimental Research Mar 2005;29(3):395-401. (Pubitemid 40446132)
30. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Anthenelli R, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology Feb 2006;26(1):13-20. (Pubitemid 43167084)
31. Kranzler HR, Burleson JA, Korner P, DelBoca FK, Bohn MJ, Brown J, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry Mar 1995;152(3):391-397.
32. Farren CK, Scimeca M, Wu R, Malley SO. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug and Alcohol Dependence Jan 1 2009;99(1-3):317-321.
33. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. American Journal of Psychiatry Jun 2010;167(6):668-675.
34. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association Mar 13 1996; 275(10):761-767. (Pubitemid 26087197)
35. Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. Journal of Clinical Psychiatry May 2008;69(5):701-705. (Pubitemid 351838678)
36. Stedman M, Pettinati H, Brown ES, Kotz M, Calabrese JR, Raines S. A doubleblind, placebo-controlled study with Quetiapine as adjunct therapy with lithium or divalproex in biopolar I patients with coexisting alcohol dependence. Alcoholism: Clinical and Experimental Research 2010;34(10):1822-1831.
37. Baltieri DA, De Andrade AG. Efficacy of acamprosate in the treatment of alcoholdependent outpatients. Revista Brasileira de Psiquiatria 2003;25(3):156-159. (Pubitemid 37122014)
38. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcoholism: Clinical and Experimental Research May 1998;22(3):573-579. (Pubitemid 28242460)
39. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism Nov-Dec 2000;35(6):587-593.
40. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol and Alcoholism Mar-Apr 2000;35(2):176-187. (Pubitemid 30248621)
41. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: A doubleblind placebo-controlled study in Spain. Alcohol and Alcoholism Sep-Oct 2001; 36(5):413-418. (Pubitemid 32851423)
42. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry Jan 2003;60(1):92-99. (Pubitemid 36070869)
43. Lhuintre JP, Moore N, Tran G, Stern L, Langrenon S, Daoust S, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol and Alcoholism 1990;25(6):613-622.
44. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. Journal of Psychiatric Research Aug 2006; 40(5):383-393. (Pubitemid 43816589)
45. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multicentre, randomized, double-blind, placebo-controlled trial. Addiction Oct 2006;101 (10):1451-1462. (Pubitemid 44337770)
46. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcoholdependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol and Alcoholism Mar-Apr 2003;38(2):135-141. (Pubitemid 36372402)
47. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry Jul 1997;171:73-77.
48. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction Nov 1997;92(11):1537-1546. (Pubitemid 27499564)
49. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Archives of General Psychiatry 1996;53(8):673-680.
50. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: Aplacebo-controlled study. Alcohol and Alcoholism 2000;35(2):202-209. (Pubitemid 30248625)
51. Whitworth AB, Oberbauer H, Fleischhacker WW, Lesch OM, Walter H, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-1442. (Pubitemid 26161206)
52. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: A randomized controlled efficacy study in a standard clinical setting. Journal of the Study of Alcohol. Jan 2004; 65(1):136-139. (Pubitemid 38200627)
53. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism Mar 1995;30(2):239-247.
54. Soyka M, Sass H. Acamprosate: A new pharmacotherapeutic approach to relapse prevention in alcoholism-Preliminary data. Alcohol and Alcoholism Supplement 1994;2:531-536.
55. Jellinek D, Alexianen KB. Acamprosate and prevention of relapse in alcoholics:Results of a randomized, placebo-controlled, double blind study in outpatient alcoholics in the Netherlands, Belgium and Luxembourg. European Addiction Research 1997;3:129-137.
56. Geerlings PJ, Ansoms C, Van Den Brink W. Acamprosate and prevention of relapse in alcoholics. European Addiction Research 1997;3:129-137.
57. Kiritze-Topor P, Huas D, Rosenzweig C, Comte S, Paille F, Lehert P. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol and Alcoholism Nov-Dec 2004;39(6):520-527. (Pubitemid 39534535)
58. Mason BJ. Acamprosate for alcohol dependence: An update for the clinician. Focus 2006;4:505-511.
59. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results 262 / MILLER, BOOK AND STEWART of a placebo-controlled trial. American Journal of Psychiatry Nov 1999;156(11): 1758-1764. (Pubitemid 29517569)
60. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, et al. A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research Jul 2003;27(7):1142-1149. (Pubitemid 36890391)
61. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. Journal of the American Medical Association Apr 6 2005;293(13):1617-1625. (Pubitemid 40471792)
62. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: Results from a German multicenter study. Journal of Clinical Psychopharmacology Dec 2002;22(6):592-598. (Pubitemid 35416785)
63. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: Results from a multicenter clinical trial. Alcoholism: Clinical and Experimental Research Sep 2002;26(9):1381-1387.
64. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology Jun 2001;21(3):287-292. (Pubitemid 32452933)
65. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, et al. Effectiveness of naltrexone in a community treatment program. Alcoholism: Clinical and Experimental Research Nov 2004; 28(11):1710-1717. (Pubitemid 39551832)
66. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology May 2000;22(5):493-503. (Pubitemid 30145617)
67. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research Jul 2004;28(7):1051-1059. (Pubitemid 38955203)
68. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine Dec 13 2001; 345(24):1734-1739.
69. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: A randomised controlled trial of effectiveness in a standard clinical setting. Medical Journal of Australia Jun 3 2002;176(11):530-534. (Pubitemid 34649401)
70. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: A randomized controlled trial. Addiction Nov 2001;96(11): 1565-1573.
71. O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: A randomized controlled trial. Alcoholism: Clinical and Experimental Research Jul 2008;32(7):1271-1283.
72. O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials. Archives of Internal Medicine Jul 28 2003; 163(14):1695-1704. (Pubitemid 36898958)
73. O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: A randomized controlled trial. Alcoholism: Clinical and Experimental Research Apr 2007; 31(4) :625-634. (Pubitemid 46434899)
74. Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcoholism: Clinical and Experimental Research Jul 2008;32(7):1299-1308.
75. Oslin DW, Pettinati H, Volpicelli JR. Alcoholism treatment adherence: Older age predicts better adherence and drinking outcomes. American Journal of Geriatric Psychiatry Nov-Dec 2002;10(6):740-747. (Pubitemid 35315710)
76. Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. Journal of Clinical Psychopharmacology Apr 2007;27(2):160-165. (Pubitemid 46594932)
77. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biology and Psychiatry Oct 1 2006;60(7):777-783. (Pubitemid 44427772)
78. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T. Naltrexone versus acamprosate: One year follow-up of alcohol dependence treatment. Alcohol and Alcoholism Sep-Oct 2001;36(5):419-425. (Pubitemid 32851424)
79. Rubio G, Manzanares J, Lopez-Munoz F, Alamo C, Ponce G, Jimenez-Arriero MA, et al. Naltrexone improves outcome of a controlled drinking program. Journal of Substance Abuse Treatment Dec 2002; 23(4):361-366. (Pubitemid 35477815)
80. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry Nov 1992;49(11): 876-880.
81. Ahmadi J, Ahmadi N. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. German Journal of Psychiatry 2002;5(4):85-89. (Pubitemid 37207265)
82. O'Malley S, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills for alcohol dependence. Archives of General Psychiatry 1992;49(11):881-887.
83. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Archives of General Psychiatry 1997;54(8): 737-742.
84. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vongnia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet Dec 8 2007;370(9603):1915-1922. (Pubitemid 350192657)
85. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebocontrolled trial. Alcoholism: Clinical and Experimental Research Jul 21 2010;34(11): 1849-1857.
86. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology Feb 2008;28(1):5-12.
87. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: A randomized double-blind placebo-controlled multicenter study. Alcoholism: Clinical and Experimental Research 2007; 31(7): 1179-1187. (Pubitemid 46934385)
88. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebocontrolled study of oral nalmefene for alcohol dependence. Archives of General Psychiatry Aug 1999;56(8):719-724. (Pubitemid 29357733)
89. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. Journal of he American Medical Association Aug 23-30 2000;284(8):963-971. (Pubitemid 30659126)
90. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcoholism: Clinical and Experimental Research 1994;18(4):879-885. (Pubitemid 24264108)
91. Longabaugh R, Wirtz PW, Gulliver SB, Davidson D. Extended naltrexone and broad spectrum treatment or motivational enhancement therapy. Psychopharmacology (Berl) Oct 2009;206(3):367-376.
92. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcoholism: Clinical and Experimental Research Nov 2001;25(11):1634-1647. (Pubitemid 33104926)
93. Hammarberg A, Wennberg P, Beck O, Franck J. A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol and Alcoholism 2004;39(3):251-255. (Pubitemid 38578743)
94. Wetzel H, Szegedi A, Scheurich A, Lörch B, Schläfke D, Sittinger H, et al. Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: A randomized controlled study. Journal of Clinical Psychiatry 2004;65:1406-1413.
95. De Wildt WA, Schippers GM, Van Den Brink W, Potgieter AS, Deckers F, Bets D. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol and Alcoholism Jul-Aug 2002;37(4): 375-382.
96. Soyka M, Preuss U, Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. Drugs: Research and Development 2002;3(1):1-12. (Pubitemid 37062591)
97. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews 2010 2010;9: 1-11.
98. Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet 1997;350:185-186. (Pubitemid 27303630)
99. Oroszi G, Anton R, O'Malley S, Swift R, Pettinati H, Couper D, et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: A haplotype-based approach. Alcoholism: Clinical and Experimental Research 2009;33(3):383-393.
100. Narayana WCPL, Gupta SLA, Sharma WCP. Use of Anti-Craving Agents in Soldiers with Alcohol Dependence Syndrome, Medical Journal Armed Forces India 2008;64(4):320-324.
101. Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, et al. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcoholism: Clinical & Experimental Research April 1995;19(2):462-468.
102. Davidson D, Gulliver SB, Longabaugh R, Wirtz PW, Swift R. Building better cognitive-behavioral therapy: As broad-spectrum treatment more effective than motivational-enhancement therapy for alcohol-dependent patients treated with naltrexone? Journal of Studies on Alcohol and Drugs March 2007;68(2):238-247.
103. Davidson D, Wirtz PW, Gulliver SB, Longabaugh R. Naltrexone's Suppressant Effects on Drinking are Limited to the First 3 Months of Treatment. Psychopharmacology May 2007;194(1):1-10. (Pubitemid 47282730)